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7RESEARCH Open AccessNOTCH ligands JAG1 and JAG2 as critical pro-
survival factors in childhood medulloblastoma
Giulio Fiaschetti1, Christina Schroeder3, Deborah Castelletti1, Alexandre Arcaro3, Frank Westermann2,
Martin Baumgartner1, Tarek Shalaby1 and Michael A Grotzer1*Abstract
Medulloblastoma (MB), the most common pediatric malignant brain cancer, typically arises as pathological result of
deregulated developmental pathways, including the NOTCH signaling cascade. Unlike the evidence supporting a
role for NOTCH receptors in MB development, the pathological functions of NOTCH ligands remain largely
unexplored. By examining the expression in large cohorts of MB primary tumors, and in established in vitro MB
models, this research study demonstrates that MB cells bear abnormal levels of distinct NOTCH ligands. We
explored the potential association between NOTCH ligands and the clinical outcome of MB patients, and
investigated the rational of inhibiting NOTCH signaling by targeting specific ligands to ultimately provide
therapeutic benefits in MB. The research revealed a significant over-expression of ligand JAG1 in the vast majority of
MBs, and proved that JAG1 mediates pro-proliferative signals via activation of NOTCH2 receptor and induction of
HES1 expression, thus representing an attractive therapeutic target. Furthermore, we could identify a clinically
relevant association between ligand JAG2 and the oncogene MYC, specific for MYC-driven Group 3 MB cases. We
describe for the first time a mechanistic link between the oncogene MYC and NOTCH pathway in MB, by identifying
JAG2 as MYC target, and by showing that MB cells acquire induced expression of JAG2 through MYC-induced
transcriptional activation. Finally, the positive correlation of MYC and JAG2 also with aggressive anaplastic tumors
and highly metastatic MB stages suggested that high JAG2 expression may be useful as additional marker to
identify aggressive MBs.
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Medulloblastoma (MB) is the most common pediatric ma-
lignant brain cancer, accounting for approximately 20% of
primary central nervous system neoplasms in this age
group [1]. Because of the significant rate of mortality and
treatment-related morbidity, further understanding of the
molecular biology of MB is needed to improve current
treatment regimens and discover novel and more effective
molecular-targeted therapies. Four distinct MB subgroups
have been identified based on common molecular
alterations: WNT tumors are characterized by activated
Wingless pathway and carry a favorable prognosis under
current treatment regimens; SHH tumors, which possess
active Sonic Hedgehog signaling, and Group 4 tumors,* Correspondence: Michael.Grotzer@kispi.uzh.ch
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unless otherwise stated.molecularly less well characterized, have an intermediate
prognosis; Group 3 tumors are characterized by high
levels of the oncogene MYC and associated with poor
prognosis [2]. A molecular-based classification of MB is a
crucial step towards optimized treatment schemes aiming
at improving risk-benefit therapeutic profiles. One further
layer of complexity is the identification of key biological
alterations to be selectively targeted by tailored therapies.
MBs are heterogeneous cerebellar tumors, which com-
monly arise as the pathological result of deregulated de-
velopmental pathways, including the NOTCH cascade
[3,4]. NOTCH signaling is required for the physiological
development of the cerebellum during embryogenesis,
controlling cell differentiation, proliferation, and apoptosis
[5]. NOTCH cascade involves functionally non-redundant
genes that appear to exert unique and specific functions
[6]. Activation of the canonical NOTCH cascade requires
the interaction of ligands (JAG1, JAG2, DLL1, DLL3, andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fiaschetti et al. Acta Neuropathologica Communications 2014, 2:39 Page 2 of 14
http://www.actaneurocomms.org/content/2/1/39DLL4) with receptors (NOTCH 1-4) [7]. Ligand binding
triggers the proteolytic cleavage of NOTCH receptors,
which is mediated by distinct enzymes, including γ-secre-
tase. Once released into the cytoplasm, the NOTCH intra-
cellular domain (NICD) translocates into the nucleus and
activates a series of transcriptional regulatory events with
context-dependent phenotypic consequences [7]. The spa-
tial and temporal expression of receptors and ligands re-
sults in diverse heterogeneous cellular responses that can
be cell- and tissue-specific, due to cross-talk with other
pathways and the cellular microenvironment [8,9]. A
growing body of evidence suggests that the ligands also
have an intrinsic signaling activity, independent of cano-
nical NOTCH, which may account for the pleiotropic ef-
fects of the NOTCH signaling [10].
Deregulation of NOTCH receptors and ligands has been
described in a wide variety of human tumors, including
pediatric malignancies, such as leukemia, glioblastoma,
and neuroblastoma [11-15]. Given the important role of
NOTCH signaling in both normal and pathologic cerebel-
lum development, it is not surprising that defects in this
pathway are also associated with MB development. In par-
ticular, oncogenic properties of NOTCH2 receptor have
been associated with MB tumor proliferation, and high
expression of the best-characterized NOTCH target gene,
HES1, has been associated with poor clinical outcome
[16,17]. However, to date the potential pathological func-
tions of NOTCH ligands in MB remain largely unex-
plored. We hypothesized that the abnormal expression of
NOTCH ligands in MB cells could trigger an alteration of
the NOTCH cascade. Therefore, we investigated NOTCH
ligands expression in MB primary samples and in in vitro
MB models, we examined the potential association be-
tween NOTCH ligands and the clinical outcome of MB
patients, and explored the rational of inhibiting NOTCH
signaling by targeting specific ligands to ultimately provide
therapeutic benefits in MB.
Materials and methods
Human MB primary samples and human-derived MB
cell lines
The tumor material used in this study originates from ar-
chival MB samples from patients treated at the University
Children’s Hospital of Zürich, Switzerland (n = 47, forma-
lin-fixed paraffin-embedded MB samples). All tissue spe-
cimens used were obtained from the Swiss Pediatric
Oncology Group (SPOG) Tumor Bank. Written informed
consent was obtained from each patient by the hospital
that provided the tissue samples. The use of SPOG Tumor
Bank tissue samples for cancer research purposes was ap-
proved by the Ethical Review Board of Zurich (Ref. Nr.
StV-18/02). MB cell lines were cultured as previously pub-
lished [18,19] and maintained at 37°C in a humidified at-
mosphere with 5% CO2. DAOY human MB cells werepurchased from the American Type Culture Collection
(ATCC - Manassas, VA, USA). D341, D425, UW-228-2,
and Med-1 human MB cells were the kind gift of
Dr. Henry Friedman (Duke University, Durham). The
stable clones DAOY V11 (empty vector transfected) and
DAOY M2.1 (MYC vector transfected) were maintained
in selective medium in the presence of 500 mg/ml G418
[20]. MB cells were grown as neuro-spheres in neurobasal
medium added with B-27 Supplement (GIBCO - Life
Technologies Grand Island, NY, USA), recombinant hu-
man EGF (20 ng/ml), and basic FGF (10 ng/ml) (R & D
Systems Inc., Minneapolis, MN 55413 USA) in corning
ultra-low binding 24-well plates (Sigma-Aldrich, St. Louis,
MO, USA).Gene expression profiling studies of MB primary samples
MB expression profiles were generated on Affymetrix
133A [21]; Affymetrix 133plus 2.0 [22,23]; Affymetrix
Human Gene 1.1 ST [24]; or Affymetrix exon 1.0 arrays
[25,26]. The datasets used in this study were comparable
regarding most patient characteristics [27]. The human
normal cerebellum expression profile was generated with
Affymetrix 133plus 2.0 [28]. Data are accessible through
the open access platform R2 for visualization and ana-
lysis of the microarray data (http://r2.amc.nl).RNA analysis by qRT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Basel, Switzerland) following the manufactu-
rer’s instructions. After enzymatic digestion of DNA with
RNase-free DNase (Qiagen), 0.5-1 μg of total RNA was
used as the template for reverse transcription employing
random hexamer primers and the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems - Life
Technologies Grand Island, NY, USA). For the qRT-PCR
reaction, Gene Expression Master Mix (Applied Biosys-
tems) was used, and the protocol was optimized for the
ABI7900HT reader (Applied Biosystems). Probe-primer
solutions specific for the following genes (purchased from
Applied Biosystems) were used: MYC (Hs00153408_m1),
JAG2 (Hs00171432_m1), JAG1 (Hs01070032_m1), and
HES1 (Hs00172878_m1). Normal human adult cerebellum
mRNA samples (Clontech-Takara Bio Europe, Saint-
Germain-en-Laye, France) (R12340039-50, AMS Biotech-
nology Limited, 184 Park Drive, Milton Park, Abingdon
OX14 4SE, UK.) and normal human fetal (40 weeks) cere-
bellum mRNA samples (R1244039-50, AMS Biotech-
nology) were used as a reference. The relative gene
expression was calculated for each gene of interest using
the ΔΔCT method, in which cycle threshold (CT) values
were normalized to the housekeeping genes succinate de-
hydrogenase complex subunit A (SDHA) (Hs00188166_m1)
and 18 s (Hs99999901_s1).
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Genomic DNA was extracted and precipitated with
a MYC-specific antibody to enrich MYC-binding pro-
moter sequences, which were hybridized to a promoter
oligo-array as previously described [29]. The genomic
positions for probes and their enrichment ratios are pro-
vided for MYC at the JAG2 locus. The horizontal red
line indicates the median enrichment ratio for MYC ver-
sus the input, as calculated from all probes for chromo-
some 14.
Western blot analysis
Total protein extracts were obtained from 0.5-1.5 × 106
cells lysed with RIPA buffer (50 mM Tris-Cl, pH 6.8,
100 mM NaCl, 1% Triton X-100, 0.1% SDS) supple-
mented with Complete Mini Protease Inhibitor Cocktail
(Roche-Applied Sciences) and the phosphatase inhibitors
β-glycerophosphate (20 mM) and Na3VO4 (200 μM).
Proteins were resolved by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and blotted on PVDF
membranes (GE Healthcare, Chalfont St Giles Bucking-
hamshire, UK) or Trans-Blot Turbo 0.2-μm nitrocellulose
(Bio-Rad Laboratories, Inc., Hercules, CA 94547, USA).
After binding of the primary antibodies, the signal was
detected by chemiluminescence using SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce-Thermo-
Scientific, Rockford, IL, U.S.A.). Antibody specific for
Hes1 (H-140) (sc-25392) was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz Biotechnology, Inc. Santa
Cruz, CA. U.S.A.); antibody specific for the Notch2 intra-
cellular domain (Asp1733) (ab52302) was purchased from
Abcam (Abcam plc, Cambridge, UK); antibodies specific
for Jagged-2 (C23D2) (2210), JAG1 (28H8) (2620), cleaved
Notch1 (Val1744), and MYC (9402) were obtained from
Cell Signaling Technology (Cell Signaling Technology,
Danvers, MA, U.S.A.). As a loading control, β-actin
(Sigma-Aldrich, St. Louis, MO, U.S.A.) was detected by
chemiluminescence using Pierce ECL Substrate (Pierce-
ThermoScientific).
siRNA transfection
Cells were transfected when they reached 70-80% con-
fluence in 6-well plates using either SMARTpool small
interfering RNA (siRNA) specific for JAG2 (L-017187-00),
JAG1 (L-011060-00), and MYC (L-003282-00) or siCON-
TROL non-targeting siRNA pool (D-001810-10-05) as a
control (Dharmacon, Thermo Fisher Scientific, Waltham,
MA). Each pool of siRNA was used at the final concentra-
tion of 50 nM in combination with Dharmafect 4 as the
transfection reagent (Dharmacon) according to the manu-
facturer’s instructions. After 24, 48, and 72 hours, the cells
were harvested for both mRNA and protein extraction to
assess gene expression by quantitative real-time PCR
(qRT-PCR) and immunoblotting, respectively.Cell viability, proliferation, and apoptosis analysis
Viability of MB cells was evaluated using the CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega
Corporation, Madison, WI, USA) and cell proliferation re-
agent WST-1 (05015944001) (Roche Diagnostics, Rotkreuz,
Switzerland). Additionally, the number of viable cells was
determined by trypan blue exclusion using a hemo-
cytometer. Proliferation was quantified using the chemi-
luminescence-based Cell Proliferation ELISA BrdU kit
(Roche Diagnostics). Activation of caspases 3 and 7 was
detected using the Caspase-Glo 3/7 Assay (Promega
Corporation). Histone-associated DNA fragments were
quantified using Cell Death Detection ELISAPLUS assays
(Roche Diagnostics). Data are expressed as the average
values obtained from three independent experiments.
Statistical analysis
All experiments were performed at least in triplicate. Data
are represented as the mean ± s.d. For in vitro experi-
ments, a Student’s t-test was used. P-values of <0.05 were
considered significant. Pearson’s correlation test was used
for gene correlation in patient samples. Student’s unpaired
T and Mann-Whitney tests were applied for statistical
analysis of normally and non-normally distributed sam-
ples, respectively [* < 0.05, ** < 0.01, *** < 0.001].
Results
NOTCH ligands are aberrantly expressed in
medulloblastoma
We first addressed whether MB tumors express predo-
minantly one or more of the five known NOTCH li-
gands. By analyzing their expression in three distinct
publicly available gene expression profiles of primary
MBs (total of 195 cases), we showed that tumors sam-
ples express all five NOTCH ligands, with JAG1 showing
the highest expression levels compared to the other
ligands (Figure 1a and Additional file 1: Figure S1a). The
levels of JAG2, DLL1, and DLL3 were comparable to
each other, whereas that of DLL4 was relatively lower.
Our hypothesis that MB tumors bear aberrant levels of
NOTCH ligands was verified when the expression levels
in tumors were normalized to expression in normal
cerebella (Figure 1b-f ). The analysis revealed distinct sig-
nificant aberrancies in the level of four ligands: JAG1,
JAG2, DLL1, and DLL4. We observed an over-expression
of JAG1 and DLL1 (Figure 1b and d, respectively) and a
down-regulation of JAG2 and DLL4 (Figure 1c and f,
respectively), whereas DLL3 expression in MB tumor
samples was comparable to that in cerebellum controls
(Figure 1e). The most relevant change in expression was
that of NOTCH ligand JAG1, which was significantly
overexpressed in almost all MBs (189/195), compared to
cerebellum. To a lesser extent, also the up-regulation of
DLL1, as well as the reduced expression of JAG2 and of
Figure 1 Expression of NOTCH ligands in MB primary tumors. (a) Relative mRNA expression of the indicated NOTCH ligands in a
representative gene expression dataset of 62 human MB tumors [23]. Dot plots showing relative expression of JAG1 (b), JAG2 (c), DLL1 (d), DLL3
(e), and DLL4 (f) in three independent gene expression datasets of human MB tumors: 62 samples [23]; 57 samples [22]; 76 samples [26].
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Notably, the variance of sample distribution was smaller
for JAG1 and JAG2, both in MB tumors and control
samples, whereas the expression levels of DLL1, DLL3,
and DLL4 demonstrated greater variation (Figure 1a and
Additional file 1: Figure S1a and b). Together these find-
ings confirmed that MB tumors harbor abnormal levels
of distinct NOTCH ligands, which likely results in a
broad alteration of the fine-tuning regulation of the sig-
naling pathway.
JAG1 is a survival factor mediating activation of canonical
NOTCH2 signals in medulloblastoma
Because of the relevant broad over-expression of JAG1 in
MB primary samples, we focused this section of the re-
search on the analysis of the biological role of this specific
NOTCH ligand. To validate the up-regulation observed in
MB gene expression profiles, JAG1 mRNA levels were
quantified in an additional independent cohort of 47 MB
primary samples collected at the Children’s Hospital of
Zurich. Consistent with the previous findings, JAG1 was
overexpressed in 74% (35/47) of MB cases compared to
normal cerebellum (Figure 2a). These findings were fur-
ther verified by analyzing the protein and mRNA levels in
a representative panel of human-derived MB cell lines.
Four out of five cell lines overexpressed JAG1 compared
to normal cerebellum (Figure 2b), confirming that MBcells bear aberrantly high levels of NOTCH ligand JAG1,
also in established and characterized MB models. Notably,
D341 MB cell line, which is genetically similar to tumors
of the molecular Group 3 [30], showed a lower JAG1 ex-
pression level compared to the others (Figure 2b).
To determine whether the activation of the canonical
NOTCH pathway in MB is mediated by JAG1, we quan-
tified the levels of activated NOTCH receptors (NICD)
and of the NOTCH target gene (HES1) in MB cells upon
JAG1 depletion. siRNA-mediated silencing of JAG1
(Figure 2c and Additional file 2: Figure S2a) caused a
drastic reduction in NICD2 and HES1 expression, at the
protein and mRNA levels (Figure 2c and d, respectively),
suggesting an important role for JAG1 in canonical
NOTCH2 signaling activation. These results were fur-
ther confirmed by comparative gene expression analysis
of clinical MB samples, which showed a highly signi-
ficant positive association between JAG1 and HES1
mRNA transcript levels (Figure 2e and Additional file 2:
Figure S2b). Notably, NOTCH1 receptor did not appear
to be affected by JAG1 depletion, since no relevant changes
in NICD1 abundance could be detected (Additional file 2:
Figure S2c). Therefore, these results depict JAG1 as im-
portant activator of pro-proliferative NOTCH2 cascade
[17], and link a specific ligand to the level of HES1, whose
high expression has been associated with poor prognosis
[16,17]. Furthermore, without affecting NOTCH1, which
Figure 2 JAG1 mediates pro-survival signaling through activation of canonical NOTCH2 signaling. (a) Relative JAG1 expression in 47 fresh
frozen MB primary samples. Values represent the fold-change in JAG1 mRNA expression compared to that in normal cerebellum samples (defined
as 1). (b) JAG1 mRNA (upper panel) and protein (lower panel) expression in the indicated MB cell lines. mRNA values represent the fold-change
in JAG1 mRNA expression compared to that in normal cerebellum samples (defined as 1). (c) Protein expression of JAG1, NICD2, and HES1 in
DAOY cells at 72 hours after treatment with JAG1 siRNA compared to control siRNA. (d) HES1 mRNA relative expression in DAOY cells upon JAG1
siRNA treatment at the indicated time-points. Values represent the percent decrease in HES1 mRNA relative to the control. (e) Correlation between
JAG1 and HES1 mRNA expression in a dataset of 103 MB tumors [25]. r: Pearson’s value; p: p values. Proliferation (f), cell viability (g), caspase 3/7
activation (h), and histone-associated DNA fragments (i) of DAOY cells at 48 hours after JAG1 siRNA treatment or at the indicated time-points
compared to control siRNA. Percent decrease in the number of colonies (j) and neuro-spheres (k) formed by DAOY cells 72 and 120 hours,
respectively, following JAG1 siRNA treatment compared to control siRNA. (k, right panel) Representative image of DAOY-derived neuro-spheres
upon treatment with JAG1 siRNA and control siRNA.
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[17], JAG1 appears to specifically mediate pro-survival
NOTCH2 signals in MB.
Indeed, JAG1 depletion negatively affected prolifera-
tion rate of MB cells (Figure 2f ), and induced activation
of the apoptotic machinery through enhanced caspase 3
and 7 activity, which led to an increase in apoptotic
histone-associated DNA fragments and reduction of cell
viability (Figure 2g, h, and i). Moreover, JAG1-depleted
cells were unable to grow clonally (Figure 2j), and the
capability of these cells to form neuro-spheres was re-
duced (Figure 2k), further supporting the notion that
JAG1 has a key role in maintaining NOTCH-related
pro-survival functions in MB cells.
Altogether, the relevant high expression level of JAG1
in the vast majority of tested MB samples, and the im-
portant role in promoting cell proliferation and survival,
all pointed at JAG1 as a key player in canonical NOTCH
activation and render this NOTCH ligand a potential
target for novel selective strategies aimed at NOTCH in-
hibition in MB.
Molecular subgroup-specific analysis reveals high levels
of NOTCH ligand JAG2 in MYC-driven Group 3 tumors
To date, the distribution and potential role of NOTCH
ligands within the defined MB molecular sub-groups is
unknown. We therefore examined NOTCH ligands ex-
pression levels across sub-groups in two distinct cohorts
of MB primary samples with available annotation for mo-
lecular subgroups (n = 388) (Figure 3a-d and Additional
file 3: Figure S3a-e). On one hand, the analysis confirmed
that the overexpression of JAG1 is a common feature
across all four MB molecular subtypes (Figure 3a and
Additional file 3: Figure S3a), thus highlighting the poten-
tial benefit of targeting JAG1 for the treatment of MB tu-
mors of different origin. On the other hand, the study
revealed distinct patterns of expression of other NOTCH
ligands across subgroups. In particular, we noticed the pre-
sence of a subpopulation of Group 3 cases expressing high
JAG2 levels (Figure 3b and Additional file 3: Figure S3b),
in contrast to the previous observation of a broad JAG2
under-expression in MB tumors (Figure1c). Additionally,
we could detect an up-regulation of NOTCH ligand DLL1
in Group 4 cases (Figure 3c and Additional file 3: Figure
S3c), and a down-regulation of DLL3 in Groups 3 and 4
tumors (Figure 3d and Additional file 3: Figure S3d).
No significant differences in DLL4 expression were ob-
served across the four MB subgroups (Additional file 3:
Figure S3e).
Given the established oncogenic role of MYC in Group
3 tumors [23,31] (Additional file 3: Figure S3f), we next
sought to investigate the potential correlation between the
oncogene MYC and JAG2, whose expression was found
unexpectedly high in Group 3 tumors. Strikingly, genecorrelation analysis based on distinct MB gene expression
profiles revealed a significant positive correlation of MYC
and JAG2 (Figure 3e and Additional file 3: Figure S3g).
Furthermore, this correlation in expression was specific
for Group 3 MB samples (Figure 3f and Additional file 3:
Figure S3h), thus suggesting a link between one particular
NOTCH ligand and the oncogene MYC in a molecularly
defined patient population. Indeed, a subset of WNT MBs
also possess high MYC levels [2] (Additional file 3: Figure
S3f), but neither high JAG2 expression could be detected
in this subgroup (Figure 3b), nor MYC and JAG2 levels
correlate among these tumors (Additional file 3: Figure
S3h, middle panel). The relatively low JAG2 expression in
WNT tumors may reflect either distinct mechanisms
regulating NOTCH members in this subgroup and/or a
regulatory cross-talk between the WNT and NOTCH
pathways in MB.
To further confirm the microarray results on JAG2/
MYC expression correlation, their mRNA levels were
analyzed in the same cohort of 47 primary MB samples
previously examined for JAG1 expression. Regrettably,
molecular subgroup annotations were not available for
this cohort of MB tumors, nevertheless JAG2 level posi-
tively correlated with MYC expression (Additional file 3:
Figure S3i), thus confirming the previous results and fur-
ther supporting the hypothesis of the two proteins being
functionally linked.
Additionally, to gain a more comprehensive overview,
correlation analyses were performed also between MYC
and the other NOTCH ligands. A slight negative corre-
lation between MYC and DLL1 was noticed (Additional
file 3: Figure S3j). On the other hand, no relevant associ-
ation with MYC level was detected for JAG1, DLL3, or
DLL4 in primary MB samples (data not shown), thus in-
dicating that the association between MYC and JAG2,
among the NOTCH ligands, is likely exclusive and po-
tentially characteristic of Group 3 tumors.
High JAG2 expression associates with aggressive
anaplastic tumors and highly metastatic stages of
medulloblastoma
MYC-driven MB cases (Group 3) have a high risk of re-
currence, the worst outcome of the four subgroups, and a
high proportion of large cells/anaplastic (LCA) tumors
[27]. In comparative studies on tumor samples, as well as
in vitro and in vivo preclinical investigations, the LCA
variant has been associated with over-expression of the
oncogene MYC and with aggressive and invasive tumor
cell behavior [4]. Scoring for the association of the
NOTCH ligand JAG2 with MB histological subtypes
in distinct datasets with available histological details
(n = 364), we detected a significant enrichment of JAG2
expression in LCA tumors compared to classic and desmo-
plastic cases (Figure 3g and Additional file 4: Figure S4a).
Figure 3 Expression of NOTCH ligands across MB molecular subgroups and MYC/JAG2 expression correlation in MB primary tumors, in
histological MB subtypes, and in distinct metastatic MB stages. Dot plots showing relative expression (log2) of JAG1 (a), JAG2 (b), DLL1 (c),
and DLL3 (d), across MB subgroups in a representative dataset of 103 human MB tumors [25]: SHH, n = 33; WNT, n = 8; Grp3 (Group 3), n = 27;
Grp4 (Group 4), n = 35. (e) Correlation between MYC and JAG2 mRNA expression (log2) in a representative dataset of 103 human MB tumors [25].
r: Pearson’s value; p: p values. (f) Correlation study of JAG2 and MYC levels in Group 3 MB cases [25]. Box plots showing JAG2 (g) and MYC (h)
expression (log 2) according to the following MB histological variants [26]: classic (n = 51), desmoplastic (desmop.) (n = 6), and (LCA) large cells/
anaplastic (n = 17); center line = median. Box plots showing JAG2 (i) and MYC (j) expression (log 2) in MB tumors clustered according to
metastatic stage [23]: M0, n = 42; M1, n = 7; ≥M2, n = 9; center line = median.
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study in which the expression level of MYC and LCA
cases were correlated (Figure 3h and Additional file 4:
Figure S4b).
Moreover, because nearly 50% of Group 3 tumors are
metastatic at the time of diagnosis [27], we next ana-
lyzed whether the expression of JAG2 is indicative of a
higher metastatic stage in MB primary samples. In three
datasets with available metastasis details (n = 172), high
levels of JAG2 were observed in highly metastatic MB
samples (≥M2 stages) compared to M0 and M1 cases
(Figure 3i and Additional file 4: Figure S4c). Although
the limited number of highly metastatic tumors reducedthe statistical relevance of these findings, similar results
were obtained in the analysis in which MYC expression
levels were examined together with M stage in the same
MB samples (Figure 3j and Additional file 4: Figure S4d).
Regrettably, the public datasets with available informa-
tion about metastatic MB stages do not account for MB
sub-grouping signatures, and vice versa. Therefore, we
could not verify if high JAG2 expression correlated with
MB metastatic stages in Group 3 cases specifically.
Additionally, analogous analyses examined the expres-
sion of the other NOTCH ligands in distinct histological
MB subtypes and metastatic stages. However, none of
the other ligands could be robustly associated with the
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summary, the positive and specific correlation between
MYC and JAG2 for LCA tumors and highly metastatic
MB stages is consistent with the Group 3-specific associ-
ation between MYC and JAG2. This further strengthens
the notion of a functional interaction between these two
proteins and suggests that high JAG2 level may be indi-
cative of aggressive MB tumors.
NOTCH ligand JAG2 is a MYC target gene in
medulloblastoma
Given the extensive evidence correlating MYC and JAG2,
we next investigated in greater detail the mechanistic link
between this NOTCH ligand and the oncogene. To assess
whether in MB JAG2 expression is MYC-dependent, first
we compared JAG2 and MYC levels in a panel of human
MB cell lines. Remarkably, JAG2 expression was high at
the mRNA and protein levels in the high-expressing MYC
cell lines (D341 and D425), whereas JAG2 levels were
lower in the low-expressing MYC MB cell lines (DAOY
and UW-228) (Figure 4a). MYC-dependent JAG2 ex-
pression was experimentally further confirmed in MB cells
genetically manipulated to have either increased or de-
creased MYC expression. In MB cells stably transfected
with a MYC expression construct (DAOY M2.1), both the
mRNA and protein levels of JAG2 were considerably
higher compared to wild-type- and empty vector-trans-
fected cells (Figure 4b). Increased JAG2 expression in
M2.1 cells was indeed MYC-dependent because MYC
overexpression-induced JAG2 levels were blunted follo-
wing MYC depletion by siRNA (Figure 4c). Unexpectedly,
after 72 hours of JAG2 silencing a moderate decrease in
MYC protein abundance was observed. However, the ana-
lysis of MYC mRNA level following JAG2 siRNA showed
a very small and statistically in-significant decrease in ex-
pression only after 72 hours (Additional file 4: Figure S4e).
Because alteration of MYC expression did not take place
at earlier time-points, these results suggested that the ob-
served effect at the protein level is likely independent of
transcriptional regulation.
Furthermore, to verify if the oncogene MYC can modu-
late the transcription of NOTCH ligand JAG2, we exa-
mined by chromatin immunoprecipitation whether MYC,
as transcription factor, was bound to the promoter region
of JAG2 in a panel of MB cell lines. Genomic DNA was
extracted and precipitated with a MYC-specific antibody
to enrich MYC-binding promoter sequences, which were
then hybridized to a promoter oligo-array [29]. An enrich-
ment of DNA fragments surrounding the transcriptional
start site of JAG2 was detected (Figure 4d and Additional
file 5: Figure S5a), indicating that MYC is indeed able
to bind the JAG2 promoter region and thus potentially
capable of modulating its expression. Notably, higher
amounts of MYC protein were detected at the JAG2promoter in a subset of cell lines with high MYC levels
(e.g., D341 and D458 cells) compared to those with low
MYC levels (e.g., DAOY and UW-228). In agreement with
recent findings describing MYC as a universal amplifier
rather than an on-off transcriptional switcher [32], our
experimental evidence suggests that in tumor cells ex-
pressing high levels of MYC, this transcription factor
accumulates in the promoter regions of (already) active
genes, likely further increasing the levels of transcripts
within the cell’s gene expression program. Thus, the
identification of JAG2 as MYC target gene suggests that
constitutive MYC induction could be involved in the alter-
ation of NOTCH-related developmental programs in MB.
The oncogene MYC alters NOTCH signaling in
medulloblastoma
Finally to evaluate if JAG2 has a functional role in MYC-
driven MB pathogenesis, we examined the biological
function of JAG2 in MB cells expressing high levels
of MYC (DAOY M2.1) [20]. Upon JAG2 depletion by
siRNA transfection in cells with high MYC expression
(Additional file 5: Figure S5b), the number of cells
undergoing apoptosis was slightly increased (Figure 4e),
while proliferation concomitantly decreased (Figure 4f ).
Since MYC induction in MB cells leads to an increased
proportion of cells undergoing programmed cell death,
while overall viability is maintained through higher rate
of proliferation [20], our results suggested that JAG2
might be one of the proteins involved in the regulation
of MYC-controlled apoptosis or proliferation. However,
the mechanism underlying this regulation remains in-
completely understood. In fact, the levels of NICD2 and
of NOTCH target HES1 were not altered upon JAG2
silencing (Additional file 5: Figure S5c), indicating that
JAG2 functions are independent of canonical NOTCH
cascade activation. Moreover, although JAG2 depletion
in MB cells expressing high levels of MYC led to apop-
tosis and reduced proliferation, unexpectedly, these
phenotypical alterations were not mirrored by reduced
cell viability (Additional file 5: Figure S5d). Besides, we
noticed that JAG2 depletion caused a significant increase
in the relative mRNA and protein levels of JAG1
(Additional file 5: Figure S5e). Analogous effects were
observed when JAG2 levels were measured under condi-
tions in which JAG1 was depleted (data not shown).
Consistently, MB cell lines with high expression of
JAG2/MYC (D341 and D425; Figure 4a) also displayed
lower JAG1 levels compared to cells expressing low
MYC levels (DAOY and UW-228; Figure 2b). Thus, it is
possible that these two ligands are mutually regulated in
a manner in which the high abundance of one ligand re-
presses the expression of the other ligand and vice-versa.
Hence, increased JAG1 expression induced by JAG2 de-
pletion could provide protection from apoptosis and
Figure 4 (See legend on next page.)
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Figure 4 MYC-dependent regulation of NOTCH ligand JAG2 expression. (a) Relative mRNA expression (upper panel) of MYC (black bars, left
Y axis) and JAG2 (orange bars, right Y axis) in the indicated cell lines. Values represent the fold-change in mRNA expression relative to cerebellum
(defined as 1). Protein expression (lower panel) of MYC and JAG2 in the corresponding cell lines. (b) Relative mRNA expression (upper panel) of
MYC and JAG2 in DAOY cells and stable clones of DAOY V11, and DAOY M2.1 cells. Values represent fold-change in mRNA expression relative to
cerebellum (defined as 1). Protein expression (lower panel) of MYC and JAG2 in corresponding cells is shown. (c) MYC and JAG2 mRNA (upper panel)
and protein (lower panel) expression in DAOY M2.1 cells transfected with MYC siRNA compared to control siRNA. mRNA values represent the percent
decrease in JAG2 and MYC expression relative to control. Expression of β-actin was used as a control for western blot analysis. Statistical analysis: black
stars indicate p values relative to MYC expression; orange stars indicate p values relative to JAG2 expression. (d) ChIP-on-chip data show occupancy of
the JAG2 genomic sequence by MYC in four MB cell lines (from top to bottom: DAOY, UW-228, D458, and D341). (e) Time-dependent caspase 3/7
activation in DAOY M2.1 cells upon JAG2 siRNA treatment at the indicated time-points; values represent the percent increase in caspase 3/7 activity
relative to control. (f) Proliferation status of DAOY cells, DAOY V11, DAOY M2.1, and DAOY M2.1 cells at 48 hours after JAG2 siRNA treatment compared
to control siRNA. Caspase 3/7 activation at 48 hours after treatment with GSI in the indicated cell lines (g) and DAOY-derived clones (h). Low MYC cells:
DAOY; high MYC cells: DAOY M2.1. Values represent the percent increase in caspase 3/7 activity relative to control siRNA.
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The inverse correlation between JAG1 and JAG2 expres-
sion was additionally verified by the analysis of MB cells
bearing different level of MYC/JAG2. In high-MYC cells
(DAOY M2.1), parallel with the high JAG2 expression in-
duced by MYC, JAG1 expression was lower (Additional
file 5: Figure S5f). Consistently, JAG1 level increased upon
JAG2 reduction triggered by MYC knockdown (Add-
itional file 5: Figure S5g). Interestingly, in cells expressing
high levels of MYC/JAG2, the expression of the NOTCH
target HES1 was considerably decreased (Additional file 5:
Figure S5f), whereas HES1 expression was up-regulated
when MYC was absent and JAG1 was expressed
(Additional file 5: Figure S5g). These findings high-
lighted the key role of JAG1 in canonical NOTCH acti-
vation, and further suggested that JAG2 signals through
a non-canonical NOTCH pathway.
Finally, because MYC controls JAG2 expression and
thereby likely alters NOTCH signaling, we sought to de-
termine whether the expression levels of MYC in MB cells
impact the response to treatment with γ-secretase inhibi-
tor (GSI), a small molecule able to block the NOTCH cas-
cade. Indeed, GSI treatment at concentrations which
proved to be effective in inhibiting NOTCH cascade in
MB cells [33], showed varying responses in different MB
cell lines, correlating with the level of MYC expression.
MB cells overexpressing MYC were less sensitive to
treatment-induced apoptosis compared to low MYC cells
(Figure 4g and h) and, strikingly, sensitivity to GSI-
induced apoptosis was restored when MYC was depleted
(Figure 4h). Altogether these results indicated the exist-
ence of a finely tuned regulatory mechanism that results
in mutual regulation of JAG1 and JAG2 expression in MB
cells, and suggested that the oncogene MYC is able to
influence the NOTCH cascade, at least partially via the
transcriptional induction of JAG2 expression.
Discussion
This study shed light on the yet unexplored pathological
functions of NOTCH ligands in MB, and verified ourmain hypothesis that an alteration of NOTCH develop-
mental pathway may be caused by abnormal ligand ex-
pression. By examining the expression levels in large
cohorts of MB primary tumors and established in vitro
MB models, we demonstrated the presence of abnormal
levels of four distinct NOTCH ligands (JAG1, JAG2,
DLL1, and DLL4) in MB. By analyzing their patterns of
expression across MB molecular subgroups, we showed
that NOTCH ligand JAG1 is broadly over-expressed in
MBs, and homogeneously distributed across subgroups. In
contrast, JAG2 is generally under-expressed in tumors
compared to normal cerebellum, but a subpopulation of
MYC-driven MBs bear increased levels of this ligand. Im-
portantly, MYC/JAG2 correlation is specific for Group 3
cases, therefore suggesting a link between one particular
NOTCH ligand and the oncogene MYC in a molecularly
defined patient population. By identifying JAG2 as MYC
target, and by showing that MB cells acquire induced ex-
pression of JAG2 through MYC-induced transcriptional
activation, we described for the first time a mechanistic
link between the oncogene MYC and NOTCH pathway in
MB. These results are supported by the report from Yus-
tein et al. that described JAG2 as one of the MYC target
genes participating in tumorigenesis in a human B cell
model [34]. Together with a study describing NOTCH4 as
a MYC target [35], these two reports represent the only
experimental evidence, to our knowledge, for transcrip-
tional control of the NOTCH pathway by MYC.
Moreover, the positive and specific correlation of MYC
and JAG2 with aggressive anaplastic tumors, and highly
metastatic MB stages might represent a clinically rele-
vant finding. Because future stratification of MB patients
will likely involve the inclusion of phenotypic tumor cell
parameters, these results suggest that determining the
expression level of JAG2 may be helpful for the sub-
classification of MYC-driven MB to distinguish ag-
gressive tumors from less severe malignances. From the
clinical point of view, these results may also be relevant
for current histology-based diagnosis of MB. Indeed, the
identification of LCA MB will likely retain its prognostic
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more frequently be used in clinics; in this context, JAG2
may represent an additional potential marker for high
MYC/LCA MB tumors. Regrettably, the number of MB
samples collected in the Children’s Hospital of Zurich is
too small to conduct a meaningful survival analysis.
Moreover, the public datasets of primary MB samples,
from where the data for this study was extracted, lack
survival data. Therefore, we could not perform a survival
analysis comparing patients with or without aberrant
JAG1 or JAG2.
In addition, current MB research is intensely focusing
on developing accurate mouse models of MYC-driven
MB. To overcome MYC-induced apoptosis, two recently
developed MYC-driven mouse MB models require loss of
p53 [36,37]. Because JAG2 appeared to cooperate with
MYC to protect MYC-overexpressing cells from apop-
tosis, JAG2 induction/up-regulation could be a useful
strategy for the development of such high-MYC-expres-
sing MB animal models.
To summarize, we propose a simplified model that
illustrates NOTCH signaling induced by JAG1 and JAG2
in MB cells in the context of different levels of MYC
(Figure 5). The majority of MB tumors bear low MYC
levels and high levels of JAG1, which triggers pro-
proliferative signaling through NOTCH2. On the other
hand, a subset of MBs, and/or a subset of cells within a
given tumor, express high levels of MYC and acquire a
concomitantly increased JAG2 protein level, which likely
alters the fine-tuned NOTCH signaling cascade.
In line with previous reports showing in different
tumor models that the inhibition of NOTCH ligands
has proven effective [15,38], our study showed thatFigure 5 MYC-dependent NOTCH signaling in MB cells. Simplified sche
JAG1 and JAG2 in MB cells. (Left panel) Low MYC MB cell. (Right panel) Highinterfering with activation of the NOTCH pathway by
targeting its ligands may represent a new direction for
alternative therapeutic approaches against MB. In par-
ticular, targeting JAG1 appears to be a promising stra-
tegy. JAG1 is highly expressed in the vast majority of
MBs and homogeneously distributed across subgroups;
moreover, JAG1 depletion inhibited pro-proliferative
NOTCH2 signals and caused a decrease in expression of
HES1, which plays a central role in MB pathogenesis
[39-42]. Furthermore, NOTCH1-mediated signaling has
been associated with activation of an anti-proliferative
cascade in MB [17]; therefore, by specifically inhibiting
the JAG1-NOTCH2 axis, a survival signaling would be
specifically blocked, and side effects due to broad and
non-specific NOTCH inhibition could be avoided. In-
deed, such treatment would specifically target a cell
membrane protein that is overexpressed in MB tumors,
but not in normal cerebellum, thus likely reducing
treatment-related side effects on the developing brains
of children.
Recent approaches attempting to block NOTCH sig-
naling via inhibitors of the γ-secretase have been effec-
tive and these compounds are currently being tested in
clinical trials for the treatment of brain tumors, inclu-
ding MBs [43]. However, γ-secretase inhibitors devel-
oped thus far broadly inhibit γ-secretases and are unable
to distinguish individual NOTCH ligand/receptor inter-
actions; as a result, they also affect other pathways [44],
and such treatment is associated with intestinal toxicity
[45]. Besides, in MB a broad NOTCH inhibition will
likely also block anti-proliferative signals induced by
the NOTCH1 receptor [17]. These negative, treatment-
related consequences could be minimized by therapeuticme illustrating the MYC-dependent NOTCH molecular network involving
MYC MB cell.
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ceptors. In addition, we observed that the response of
MB cells to GSI treatment was influenced by MYC
status, although the mechanism remains incompletely
understood. Because MYC depletion reduces JAG2 and
increases JAG1 expression, thereby shifting cells from
non-canonical to canonical NOTCH signaling, it is
conceivable that the dependence on canonical NOTCH
signaling would be increased. This observation is signifi-
cant because JAG2 blockage in MYC-driven MB tumors
may cause the re-acquisition of tumor sensitivity to
treatment with γ-secretase inhibitors.
Therefore, further studies are required to determine
the benefits of such treatments in combination with
NOTCH ligand inhibition for different MB subtypes,
particularly MYC-driven tumors. Additional effort is also
needed for the development of neutralizing antibodies
and/or small molecules targeting specific NOTCH li-
gands, which should then be tested in MB animal mo-
dels to verify the benefits of such treatments.
Conclusion
This study advanced our understanding of NOTCH sig-
naling and its pathological role in MB, and investigated
for the first time the therapeutic benefits of interfering
with NOTCH pathway via the inhibition of NOTCH
ligands in MB cells. This approach represents an attrac-
tive strategy to be considered in combination with tar-
geting SHH or WNT pathways or as a side therapy to
synergize with the apoptosis-inducing effects of standard
chemo-therapeutics.
Additional files
Additional file 1: Figure S1. Expression of NOTCH ligands in MB
primary tumors and cerebellum samples. (a) Relative mRNA expression of
the indicated NOTCH ligands in two independent gene expression
datasets of human MB tumors [Left panel: 57 samples [22]; right panel: 76
samples [26]. (b) Relative mRNA expression of the indicated NOTCH
ligands in a gene expression profile dataset of human cerebellum
samples (n = 9) [28].
Additional file 2: Figure S2. JAG1 siRNA-mediated silencing and
correlation of JAG1/HES1 in primary MB tumors. (a) Relative JAG1 mRNA
expression in DAOY cells upon JAG1 siRNA treatment at the indicated
time-points. Values represent the percent decrease in JAG1 mRNA relative
to the control. (b) Correlation between JAG1 and HES1 mRNA expression
in three representative datasets of human MB tumors: left panel, 76
samples [26]; middle panel, 57 samples [22]; right panel, 62 samples [23].
r: pearson’s value; p: p values. (c) Western blot showing expression of
JAG1 and NICD1 in DAOY cells at 48 hours after JAG1 siRNA treatment
compared to control siRNA. β-actin expression was used as control.
Additional file 3: Figure S3. Validation of the expression of NOTCH
ligands across MB molecular subgroups and correlation of MYC/JAG2
expression in MB primary tumors. Dot plots showing the relative
expression (log 2) of JAG1 (a), JAG2 (b), DLL1 (c), DLL3 (d), and DLL4
(e) across MB subgroups in 285 human MB tumors [24]: SHH, n = 51;
Grp3 (Group 3), N = 46; Grp4 (Group 4), n = 188. (e and f) Dot plots
showing the relative expression of DLL4 and MYC, respectively, across MB
subgroups in two datasets. Left panel [25]: SHH, n = 33; WNT, n = 8; Grp3(Group 3), n = 27; Grp4 (Group4), n = 35. Right panel [24]: SHH, n = 51;
Grp3 (Group 3), n = 46; Grp4 (Group 4), n = 188. (g) Correlation between
MYC and JAG2 mRNA expression in 285 MB tumors [24]. r: Pearson’s
value; p: p values. (h) Correlation study of JAG2 and MYC expression
levels (log 2) across MB subgroups (SHH, WNT, Group 4) [25]. (i)
Correlation between MYC and JAG2 mRNA expression (log 2) in 47 MB
primary samples. (j) Correlation between MYC and DLL1 mRNA
expression in two datasets of 285 MB tumors (left panel) [24] and 103 MB
tumors (right panel) [25]. r: Pearson’s value; p: p values.
Additional file 4: Figure S4. High JAG2 expression in LCA MB tumors
and highly metastatic MB cases. Box plots showing JAG2 (a) and MYC
(b) expression (log 2) according to MB histological variants of MB tumors.
Left panels (n = 251) [24]: classic (n = 200), desmoplastic (desmop.)
(n = 21), and (LCA) large cells/anaplastic (n = 30). Right panels (n = 103)
[25]: classic (n = 77), desmoplastic (desmop.) (n = 16), and (LCA) large
cells/anaplastic (n = 8); center line = median. Box plots showing JAG2 (c)
and MYC (d) expression in MB tumors clustered by the metastatic stage
of MB tumors; center line = median. Left panels (n = 63): M0, n = 45; M1,
n = 5; M2, n = 4; M3, n = 9. Right panels (n = 46) [21]: M0, n = 26; M1,
n = 7; ≥M2, n = 13. (e) MYC mRNA expression in DAOY M2.1 cells upon
JAG2 siRNA at the indicated time-points. mRNA values represent the
percent decrease in MYC expression relative to siRNA control.
Additional file 5: Figure S5. Validation of MYC-dependent JAG2
expression and compensatory mechanism regulating relative JAG1/JAG2
levels. (a) MYC binding to the JAG2 promoter in four additional MB cell
lines. ChIP-on-chip data showing occupancy of the JAG2 genomic
sequence by MYC in four additional MB cell lines (from top to bottom:
D283, ONS76, PNET5, and MED8A). (b) Relative JAG2 mRNA expression in
MYC stably transfected DAOY M2.1 cells upon JAG2 siRNA treatment at
the indicated time-points. (c) Western blot showing the expression of
JAG2, NICD2, and HES1 in MYC stably transfected DAOY M2.1 cells at
48 hours after JAG2 siRNA treatment compared to control siRNA; β-actin
expression was used as a control. (d) Cell viability of MYC stably transfected
cells (DAOY M2.1) at 48 hours after JAG2 siRNA treatment compared to
control siRNA. (e) Relative JAG1 and JAG2 mRNA expression (left panel) and
protein expression (right panel) in DAOY M2.1 cells at 72 hours after JAG2
siRNA treatment. (f) Relative JAG1 and HES1 mRNA expression in DAOY
M2.1 MYC stably transfected cells (high MYC) and DAOY V11 empty vector-
transfected cells (low MYC). (g) Relative JAG1 and HES1 mRNA expression in
DAOY M2.1 cells at 48 hours after MYC siRNA compared to control siRNA.
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